Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (NCT01835236)
In HER2-positive metastatic breast cancer, trastuzumab (Herceptin®;Genentech, Inc.) based treatment is the standard of care as long as there are no contraindications to trastuzumab. Frequently, trastuzumab is being combined with taxanes in the first-line setting. However, since therapy with trastuzumab is active even in the absence of chemotherapy in HER2-positive MBC, the optimal treatment strategy either in combination or in sequence with chemotherapy is still under debate.
This randomized phase II trial is studying a new strategy for the treatment of metastatic breast cancer with HER2-positive. First-line treatment consists of trastuzumab and pertuzumab (Perjeta®; Genentech, Inc.), a treatment without chemotherapy. In case of disease progression, chemotherapy with ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) is then performed as second-line treatment. Third-line and further line therapies are performed according to the physician’s discretion. If this new therapeutic strategy is as effective and better tolerated than the conventional strategy, this would mean a serious breakthrough in the treatment of HER2-positive metastatic breast cancer.
This trial is sponsored by Swiss Group for Clinical Cancer Research. 
- Condition: Metastatic Breast Cancer
- Phase: II
- Estimated Enrollment: 208
- Start: July 2013
- Estimated Completion: June 2019
- Last verified: January 2015
Last Editorial review: July 28, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.